Zevra nets $148M PRV gain, posts Q2 profit as OLPRUVA impairment and obsolescence emerge

Zevra Therapeutics, Inc. (NASDAQ: KMPH)

Quick take: Management converted FDA approval into commercial revenue (MIPLYFFA), monetized a transferable PRV for a one‑time $148.3M net gain that materially improved cash and profit for the quarter, but wrote down an acquired product intangible (OLPRUVA) by $58.7M and took large inventory obsolescence charges - signalling commercial execution and demand issues for that asset. The company has meaningful cash & marketable securities on hand but also outstanding debt, contingent liabilities (warrants/CVR) and an active contract dispute that could drive costs.

Key facts & figures (as reported, all $ in thousands unless noted):
- Revenue Q2 2025: $25,881 (Q2 2024: $4,449). Six months to June 30, 2025: $46,282 (2024: $7,874).
- Gain on sale of PRV (one‑time): $148,325 recorded in Q2 and YTD 2025 (net proceeds $148.3M; sale closed April 1, 2025).
- Cost of product revenue (Q2 2025): $12,379; includes inventory obsolescence charge of $11,681 for Q2 (YTD inventory write‑down same amount).
- Intangible asset amortization (Q2): $1,616; impairment of intangible assets (OLPRUVA) recorded: $58,710 in Q2 and YTD 2025.
- Net income (Q2 2025): $74,707 (Q2 2024: net loss $19,925). YTD net income: $71,608 (YTD 2024: loss $36,547).
- EPS Q2 2025: basic $1.24 / diluted $1.21. YTD basic $1.20 / diluted $1.16. Weighted‑average basic shares ~54.78M.

Balance sheet & liquidity:
- Cash and cash equivalents: $47,712; Securities at fair value (current): $154,899; total cash + securities ~ $202M; company cites cash, cash equivalents and investments of $217.7M as of June 30, 2025.
- Total current assets: $226,337; Total assets: $256,277.
- Total liabilities: $139,047; long‑term debt (net): $60,692 (notes payable principal $62,566, maturity principally 2029).
- Warrant liability: $15,807; CVR liability (June 30, 2025): $1,370.
- Stockholders' equity: $117,230; accumulated deficit: $(433,681).

Operational highlights & trends inside the company:
- Commercial traction: MIPLYFFA sales ramped quickly-Q2 MIPLYFFA sales ~$21.5M (YTD ~$38.6M).
- OLPRUVA underperformance: management's refined commercial assessment led to a definitive impairment of the OLPRUVA finite‑lived intangible ($58.7M), and inventories tied to the acquired product were largely written down (raw materials fell from $7,928 to $21).
- Cost structure shifts: SG&A increased materially (Q2 SG&A $20.8M vs $12.6M prior year) reflecting commercial buildout; R&D spending declined (Q2 R&D $3.4M vs $10.5M prior year) as the company prioritizes commercialization and late‑stage programs.
- Cash generation: operating cash used YTD was $(11,823); investing provided $22,476 (PRV proceeds timing); financing provided $2,988 (equity activity small). Company states runway funded for at least next 12 months given cash & investments.

Positive aspects of the income statement
- One‑time PRV sale produced a large non‑operating gain ($148.3M) that converted an operating loss into GAAP net income for the period.
- Rapid revenue growth driven by commercial launch of MIPLYFFA (Q2 revenue +$21.4M vs prior year).
- Reduced R&D spend (reflecting completed/paused programs) improves near‑term operating cash burn.

Negative aspects of the income statement
- Large non‑cash impairment ($58.7M) tied to OLPRUVA indicates the acquired asset is not meeting prior forecasts and reduces future amortizable intangible base.
- Significant inventory obsolescence charge ($11.7M) reduces gross margin and highlights supply/demand or channel management problems (raw materials dropped sharply).
- Rising SG&A (+~$8.2M Q/Q) shows heavy commercial investment and pressure on recurring operating profitability absent one‑time gains.
- Company remains reliant on non‑recurring items (PRV) to report GAAP profits; core operating loss from product operations before other income was negative (loss from operations Q2: $(71,039)).

Other material items to watch / risks inside the company:
- Legal dispute with Commave over the AZSTARYS License Agreement - in discovery; could drive legal costs and contract risk.
- Concentration risk: single specialty pharmacy distributor for U.S. sales; single large revenue customer increases execution risk.
- Debt covenants & liquidity: $100M facility (tranches) outstanding principal rules and a required minimum cash balance ($20M) while interest is SOFR + spread and some interest may be paid in kind.
- Contingent liabilities: warrants and CVRs aggregate fair value (~$17.2M liabilities at June 30, 2025); contingent CVR exposure tied to future milestones for acquired assets.
- Revenue sustainability: MIPLYFFA commercial adoption and reimbursement environment, plus competition and diagnosis rates for NPC, will determine recurring revenue trajectory.

Net snapshot - what management achieved and what still concerns investors
- Achieved: monetized PRV ($148.3M), meaningful cash/investments, clear MIPLYFFA revenue ramp, reduced R&D burn.
- Concerning: OLPRUVA impairment and inventory obsolescence show commercialization/forecast miss; higher SG&A burn; ongoing litigation risk and contingent liabilities; reliance on one distributor and on one‑time proceeds for reported GAAP profitability.

Actionable signals for investors:
- Monitor next quarters for (1) recurring MIPLYFFA revenue growth and gross margins (ex‑one‑time items), (2) inventory trend / channel fills vs sell‑through, (3) progress and expense related to Commave litigation, and (4) covenant compliance / debt paydown or refinancing activity.